Retatrutide (LY3437943): A Triple Hormone Agonist for Weight Loss and Type 2 Diabetes
Retatrutide (LY3437943) represents a significant evolution in metabolic therapy as the first triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. This novel mechanism addresses obesity and type 2 diabetes through three complementary pathways: enhancing insulin secretion, suppressing appetite, and increasing energy expenditure. For those interested in peptide therapies, you can buy GLP-3 RT through […]























